JP2022525164A - 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用 - Google Patents

遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用 Download PDF

Info

Publication number
JP2022525164A
JP2022525164A JP2021555282A JP2021555282A JP2022525164A JP 2022525164 A JP2022525164 A JP 2022525164A JP 2021555282 A JP2021555282 A JP 2021555282A JP 2021555282 A JP2021555282 A JP 2021555282A JP 2022525164 A JP2022525164 A JP 2022525164A
Authority
JP
Japan
Prior art keywords
antibody
hae
treatment
subject
seizure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021555282A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525164A5 (cg-RX-API-DMAC7.html
Inventor
メディナ,ジョアン イェシド メンディヴィル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2022525164A publication Critical patent/JP2022525164A/ja
Publication of JP2022525164A5 publication Critical patent/JP2022525164A5/ja
Priority to JP2025002888A priority Critical patent/JP2025061116A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021555282A 2019-03-14 2020-03-13 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用 Pending JP2022525164A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025002888A JP2025061116A (ja) 2019-03-14 2025-01-08 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962818189P 2019-03-14 2019-03-14
US62/818,189 2019-03-14
PCT/US2020/022535 WO2020186132A1 (en) 2019-03-14 2020-03-13 Treating hereditary angioedema attack with reduced dosage of antibodies binding to human plasma kallikrein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025002888A Division JP2025061116A (ja) 2019-03-14 2025-01-08 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用

Publications (2)

Publication Number Publication Date
JP2022525164A true JP2022525164A (ja) 2022-05-11
JP2022525164A5 JP2022525164A5 (cg-RX-API-DMAC7.html) 2023-03-20

Family

ID=70228815

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021555282A Pending JP2022525164A (ja) 2019-03-14 2020-03-13 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用
JP2025002888A Pending JP2025061116A (ja) 2019-03-14 2025-01-08 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025002888A Pending JP2025061116A (ja) 2019-03-14 2025-01-08 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用

Country Status (9)

Country Link
US (1) US20200317815A1 (cg-RX-API-DMAC7.html)
EP (1) EP3938404A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022525164A (cg-RX-API-DMAC7.html)
KR (1) KR20210142006A (cg-RX-API-DMAC7.html)
AU (1) AU2020237259A1 (cg-RX-API-DMAC7.html)
CA (1) CA3133576A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021011110A (cg-RX-API-DMAC7.html)
TW (1) TW202100561A (cg-RX-API-DMAC7.html)
WO (1) WO2020186132A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
JP2016513682A (ja) 2013-03-15 2016-05-16 ダイアックス コーポレーション 抗血漿カリクレイン抗体
ES3065185T3 (en) 2014-01-21 2026-05-04 Takeda Pharmaceuticals Co Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
AU2020392243A1 (en) 2019-11-28 2022-06-16 Regenxbio Inc. Microdystrophin gene therapy constructs and uses thereof
AU2021209045A1 (en) 2020-01-13 2022-07-28 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
CN114790245B (zh) * 2021-01-25 2026-08-11 成都康弘生物科技有限公司 一种抗体及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017503820A (ja) * 2014-01-21 2017-02-02 ダイアックス コーポレーション 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用
JP2019501886A (ja) * 2015-12-11 2019-01-24 ダイアックス コーポレーション 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
CA2180950C (en) 1994-01-11 2005-03-29 William Markland Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
PT2298278E (pt) 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017503820A (ja) * 2014-01-21 2017-02-02 ダイアックス コーポレーション 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用
JP2019501886A (ja) * 2015-12-11 2019-01-24 ダイアックス コーポレーション 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRANK, M. M. ET AL.: "Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency", PEDIATRICS, vol. 138, no. 5, JPN6024007294, 2016, pages 20160575, ISSN: 0005270074 *

Also Published As

Publication number Publication date
TW202100561A (zh) 2021-01-01
US20200317815A1 (en) 2020-10-08
KR20210142006A (ko) 2021-11-23
EP3938404A1 (en) 2022-01-19
MX2021011110A (es) 2022-01-19
CA3133576A1 (en) 2020-09-17
AU2020237259A1 (en) 2021-10-14
JP2025061116A (ja) 2025-04-10
WO2020186132A8 (en) 2020-10-15
WO2020186132A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
JP7309836B2 (ja) 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用
JP7426369B2 (ja) 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途
JP2025061116A (ja) 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用
US20230104754A1 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN116585468A (zh) 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途
JP2025186458A (ja) 小児遺伝性血管性浮腫発作を治療するための血漿カリクレイン阻害剤及びその使用
EA048026B1 (ru) Ингибиторы калликреина плазмы и их применения для лечения приступа наследственного ангионевротического отека

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240627

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250109